Phase II Trial of Bevacizumab in Combination with XELOX in Colorectal Cancer Patients with Liver Metastases (H2, H3)

Interventions: Treatment is administered every 3 weeks until evidence of progression, unacceptable toxicity, patient refusal, or for a maximum of 9 cycles. During the treatment, image assessment is repeated every 3 cycles, and if liver metastases could be converted resectable, liver resection is performed.
Primary outcome(s): resection rate of liver metastases
Study Design: Single arm Non-randomized